Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:15 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 10,549 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

NCT00591578
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil, Valsartan
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
77
States / cities
Huntsville, Alabama • Glendale, Arizona • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 1Phase 2 Interventional Results available

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100

NCT00479115
View directory record Official record
Conditions
Fanconi Anemia
Interventions
AMD3100, AmCell CliniMACs
Drug · Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 1 Interventional

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

NCT00000768
View directory record Official record
Conditions
Colitis, HIV Infections
Interventions
Glutamic acid hydrochloride, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 4 Interventional

Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose

NCT00143260
View directory record Official record
Conditions
Impotence
Interventions
Viagra (Sildenafil Citrate) 100 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Birmingham, Alabama • Homewood, Alabama • Hoover, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00871182
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled PT001, Inhaled Placebo, Tiotropium Handihaler
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Peoria, Arizona • Denver, Colorado • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 1 Interventional

Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants

NCT00008424
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
45
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 3 Interventional

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727
View directory record Official record
Conditions
Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions
ropinirole controlled-release (REQUIP CR) for RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

NCT00521586
View directory record Official record
Conditions
Influenza
Interventions
13 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 59 Years
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
41
States / cities
Chandler, Arizona • Rolling Hills Estates, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

NCT02213354
View directory record Official record
Conditions
Avian Influenza
Interventions
MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 1 Interventional

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT01767766
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma
Interventions
TGR-1202
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Sarasota, Florida • Hackensack, New Jersey • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Nov 3, 2026, 9:15 AM EST
Completed Not applicable Interventional Results available

Endurant Stent Graft System Post Approval Study (ENGAGE PAS)

NCT01379222
View directory record Official record
Conditions
Aortic Aneurysm, Abdominal
Interventions
Endurant Stent Graft System
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
24
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 3, 2026, 9:15 AM EST
Terminated Phase 1 Interventional

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

NCT04659122
View directory record Official record
Conditions
COVID-19, Undefined
Interventions
AT-100
Biological
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699972
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 1 Interventional Results available

A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

NCT04992312
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Glucagon Nasal Powder [Baqsimi]
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 4 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Jacksonville, Florida • Boise, Idaho • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 1Phase 2 Interventional Results available

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

NCT02678741
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
TLPLDC Vaccine
Drug
Lead sponsor
Elios Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

NCT01716754
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Omalizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Fresno, California • Hawaiian Gardens, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Nov 3, 2026, 9:15 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)

NCT05823766
View directory record Official record
Conditions
Traumatic Brain Injury, Post-traumatic Epilepsy
Interventions
In-Person Outcome Assessment, 3T Magnetic Resonance Imaging (MRI), Clinical Visit, Blood Draw, EEG, Telephone Outcome Assessment
Behavioral · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
9
States / cities
San Francisco, California • Charlestown, Massachusetts • Cincinnati, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 3, 2026, 9:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex and Age Ultrasound Response to Differential Jugular Vein Pressure

NCT03017937
View directory record Official record
Conditions
Concussion, Mild
Interventions
Q-collar
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 60 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 3, 2026, 9:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Clarity in Motion Phase-1 Perceptual Study of Speech Intelligibility

NCT07020728
View directory record Official record
Conditions
Healthy
Interventions
Solo: Unmasked Speech Stimuli, Raw: Fully masked speech--no motion stimuli, StatScrub: Extracted Speech--no motion stimuli, SlideSpch: Scrubbed Speech emitted from linearly moving speaker stimuli, SlideNoise: Speech Scrubbed from linearly moving and stationary noise stimuli, SlideMic: Stationary sources scrubbed from a linearly moving mic stimuli
Behavioral
Lead sponsor
Speech Technology and Applied Research Corp.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

NCT05195528
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
108
States / cities
Athens, Alabama • Cullman, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Nov 3, 2026, 9:15 AM EST
Active, not recruiting Not applicable Interventional

J-Valve TF Early Feasibility Study

NCT06034028
View directory record Official record
Conditions
Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation
Interventions
J-Valve TF System
Device
Lead sponsor
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Oak Lawn, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

NCT00157105
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
5 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Nov 3, 2026, 9:15 AM EST
Completed Phase 2 Interventional Results available

A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

NCT02993822
View directory record Official record
Conditions
Chronic Refractory Cough
Interventions
Orvepitant Maleate, Placebo
Drug
Lead sponsor
Nerre Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
46
States / cities
Chandler, Arizona • Los Angeles, California • Mission Viejo, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Nov 3, 2026, 9:15 AM EST
Recruiting Not applicable Interventional

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

NCT06057051
View directory record Official record
Conditions
Glaucoma
Interventions
iStent Infinite
Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
35 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 3, 2026, 9:15 AM EST